Cipla Limited has launched CipAir, an innovative AI-powered mobile application developed for early screening for asthma in India. The app has been integrated into Cipla's existing Breathefree ecosystem for timely asthma screening, and uses sophisticated technology to enable better respiratory care.

Key highlights About CipAir:

• CipAir is an AI-driven tool integrated with Breathefree mobile application, Cipla's respiratory care platform.

• Supported by a thorough type-audio analysis of the asthma symptoms validated clinically in a multi-center pan-India study, the app utilizes deep neural network science.

Features and Accessibility :

• The app gives recommendations on how to do three breaths into the mobile device in a quiet surrounding.

• The results are released in about a minute, based on personal data, and provide a positive/negative indication, as well as the possibility of the development of asthma.

• The Breathefree platform also provides patients with educational resources regarding lung health and professional advice.

• The app will first be available for android users and expand to iOS users soon.

Reducing the Burden of Asthma in India:

• According to a concept note prepared by the Global Burden of Disease report of India, a galloping 34.3 million residents of India are diagnosed with asthma, with mortality rates thrice that of the world average.

• The rise in the number of patients suffering loads due to increasing air pollution requires something, like CipAir, which is easy to convey for diagnosis.

Marketing Strategy:

• It is Cipla's intention to market CipAir from its Breathefree platform and the set of marketing forces across the country.

• The app continues to be upgraded to ensure the progress of asthma management in India.

Company's Vision:

• As said by Umang Vohra, Managing Director and Global CEO of Cipla, "With the help of next-generation technologies, we are transforming the face of patient care, so as to enable better outcomes for diagnostic, therapeutic, and management purposes. In CipAir, we essentially seek to provide a channel for personalized healthcare to reach beyond the hospital and help patients live a healthier life."

CipAir is therefore another momentous step for Cipla within its respiratory care strategy. In particular, it demonstrates the company's commitment to harnessing the potential of AI for better patient outcomes. Thus, the app is expected to redefine the asthma management space in India with diagnosis becoming more accessible and enabling proactiveness on the part of the patient in cataracting their condition.